Peter Michael Foundation

Background

The Peter Michael Foundation, established in 1995 and based in Sausalito, California, is a 501(c)(3) nonprofit organization dedicated to advancing innovative research, clinical trials, and applied methods for improving the detection, management, and non-invasive treatment of prostate cancer. The foundation places a particular emphasis on prostate cancer imaging research, recognizing that enhanced tumor imaging is crucial for effective cancer management and is currently underdeveloped in the context of prostate cancer.

Key Strategic Focus

The foundation's strategic focus centers on supporting leading hospitals and research universities in overcoming challenges related to obtaining government funding for cancer imaging research, which is often categorized as diagnostic rather than therapeutic. By funding research into anatomic and metabolic imaging techniques, the foundation aims to improve treatment outcomes for prostate cancer and other soft tissue cancers, including breast, kidney, and liver cancers.

Financials and Funding

In the fiscal year ending December 2023, the Peter Michael Foundation reported revenue of $830,746 and expenses totaling $849,102, resulting in a net loss of $18,356. The foundation's total assets stood at $943,557, with no liabilities reported. Notably, contributions accounted for over 100% of the total revenue, amounting to $987,887, while investment income contributed $2,927. Professional fundraising fees were reported at $102,150, representing 12% of total expenses.

Pipeline Development

The foundation has established Pelican Postdoctoral Fellowships at three prominent institutions to advance prostate cancer imaging research:

University of California, San Francisco (UCSF): Supporting Dr. Daniel Vigneron at the California Institute for Quantitative Biosciences, focusing on developing new techniques for significant advancements in anatomic and metabolic imaging of prostate cancer.

Memorial Sloan-Kettering Cancer Center: Supporting Dr. Hedvig Hricak in leading research into the development of new imaging techniques for prostate cancer.

Middlesex Hospital (UK): Supporting Dr. Mark Emberton of the Pelican Prostate Cancer Research Unit, who is the lead UK investigator of the pan-European clinical trial study of High-Intensity Focused Ultrasound (HIFU) for the treatment of prostate cancer and benign prostatic hyperplasia (BPH).

Technological Platform and Innovation

The foundation's support for research into anatomic and metabolic imaging techniques aims to enhance the detection and management of prostate cancer. By funding studies on advanced imaging methodologies, the foundation contributes to the development of non-invasive treatment options and improved diagnostic accuracy for prostate cancer and other soft tissue cancers.

Leadership Team

The Peter Michael Foundation is led by a dedicated team of volunteers:

Scott Rodde (President): Oversees the foundation's strategic initiatives and operations.

Malcolm V. Morris (Vice President): Supports the foundation's mission through leadership and governance.

Michael Meyers (Secretary): Manages administrative responsibilities and ensures compliance with regulatory requirements.

All key personnel serve on a voluntary basis without compensation.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within the foundation's leadership team.

Competitor Profile

In the nonprofit sector focused on prostate cancer research and support, several organizations operate with similar missions:

Prostate Cancer Foundation (PCF): A leading philanthropic organization funding and accelerating prostate cancer research globally.

ZERO - The End of Prostate Cancer: A nonprofit dedicated to ending prostate cancer through awareness, outreach, advocacy, and research funding.

Movember Foundation: A global charity raising funds and awareness for men's health issues, including prostate cancer, through annual fundraising campaigns.

These organizations contribute to the broader landscape of prostate cancer research and support, each with unique approaches and areas of focus.

Strategic Collaborations and Partnerships

The Peter Michael Foundation collaborates with leading research institutions and hospitals to advance prostate cancer imaging research. By funding postdoctoral fellowships and supporting clinical trials, the foundation fosters partnerships that drive innovation and improve patient outcomes.

Operational Insights

The foundation's strategic focus on imaging research addresses a critical gap in prostate cancer detection and management. By supporting research that may not receive sufficient government funding, the foundation positions itself as a key player in advancing non-invasive diagnostic and treatment options for prostate cancer.

Strategic Opportunities and Future Directions

Looking ahead, the Peter Michael Foundation aims to expand its support for innovative imaging research and clinical trials. By continuing to fund postdoctoral fellowships and fostering collaborations with leading institutions, the foundation seeks to drive advancements in prostate cancer detection and treatment, ultimately improving patient outcomes and quality of life.